Cargando…
Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells
The triple-negative breast cancer (TNBC) subtype is enriched in cancer stem cells (CSCs) and clinically correlated with the highest rate of recurrence. Several studies implicate the RSK pathway as being pivotal for the growth and proliferation of CSCs, which are postulated to drive tumor relapse. We...
Autores principales: | Davies, Alastair H., Reipas, Kristen, Hu, Kaiji, Berns, Rachel, Firmino, Natalie, Stratford, Anna L., Dunn, Sandra E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653026/ https://www.ncbi.nlm.nih.gov/pubmed/26011941 |
Ejemplares similares
-
Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1)
por: Reipas, Kristen M., et al.
Publicado: (2013) -
The Fhit protein: an opportunity to overcome chemoresistance
por: Gaudio, Eugenio, et al.
Publicado: (2016) -
Cisplatin for cancer therapy and overcoming chemoresistance
por: Ranasinghe, Ranmali, et al.
Publicado: (2022) -
rSK1 in Rat Neurons: A Controller of Membrane rSK2?
por: Autuori, Eleonora, et al.
Publicado: (2019) -
mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer
por: Kumari, Anju, et al.
Publicado: (2023)